Aug 13, 2025 10:05AM Benchmark Reiterates Hold Rating on AbCellera Biologics (ABCL)

Aug 7, 2025 04:23PM AbCellera (ABCL) Tops Q2 EPS by 2c

Jul 7, 2025 06:20AM Leerink Partners Assumes AbCellera Biologics (ABCL) at Outperform, PT $5

May 30, 2025 01:00PM AbCellera (ABCL) Cleared to Initiate a Phase 1 Clinical Trial of ABCL575 in Canada

May 16, 2025 10:06AM Truist Slashes AbCellera Biologics (ABCL) Stock PT from $28 to $10

May 14, 2025 05:00PM AbCellera (ABCL) Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025 03:30PM AbCellera's (ABCL) Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 8, 2025 04:05PM AbCellera (ABCL) Misses Q1 EPS by 1c

Apr 29, 2025 03:01PM AbCellera (ABCL) Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers

Mar 3, 2025 09:41AM Benchmark Reiterates Hold Rating on AbCellera Biologics (ABCL)

Feb 27, 2025 04:19PM AbCellera (ABCL) reported revenue at $5.1 million

Jan 13, 2025 09:09AM AbCellera (ABCL) Expands Collaboration with AbbVie (ABBV) to Develop Novel T-Cell Engagers for Oncology

Nov 5, 2024 08:14AM AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital

Nov 4, 2024 04:08PM AbCellera (ABCL) Tops Q3 EPS by 1c

Aug 23, 2024 11:57AM KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL)

Aug 20, 2024 09:15AM Benchmark Downgrades AbCellera Biologics (ABCL) to Hold

Aug 6, 2024 04:08PM AbCellera (ABCL) Tops Q2 EPS by 1c

Jul 31, 2024 09:01AM AbCellera (ABCL) and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 28, 2024 10:34AM TD Cowen Reiterates Buy Rating on AbCellera Biologics (ABCL)